Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Health Canada has cleared YM BioSciences to go ahead with a phase I/II study into its drug, nimotuzumab, in patients with non-small-cell lung cancer.
Subscribe to our email newsletter
The trial will compare the effects of the combination of nimotuzumab with radiation, against radiation alone in patients with stage IIB and III forms of the disease. The company believes that the drug will have the effect of increasing the effectiveness of radiation therapy.
“YM has achieved another milestone by further broadening the clinical development program for nimotuzumab. We expect that the population of essentially untreatable patients with NSCLC, whose only option is to be treated palliatively with radiation, will benefit from the addition of our antibody to this treatment modality,” said David Allan, chairman and CEO of YM.
The antibody is also about to go into a phase III trial in an indication to treat brain cancer, and is currently undergoing a phase II monotherapy trial in Europe in patients with advanced metastatic pancreatic cancer.